These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

624 related items for PubMed ID: 19164318

  • 1. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
    Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N.
    Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
    [Abstract] [Full Text] [Related]

  • 2. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
    Heras P, Kritikos K, Hatzopoulos A, Mitsibounas D.
    Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
    [Abstract] [Full Text] [Related]

  • 3. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 4. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF.
    J Clin Oncol; 2005 Apr 20; 23(12):2606-17. PubMed ID: 15452187
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.
    Suzuki Y, Tokuda Y, Fujiwara Y, Minami H, Ohashi Y, Saijo N.
    Jpn J Clin Oncol; 2008 Mar 20; 38(3):214-21. PubMed ID: 18296425
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun 20; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

  • 10. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN.
    J Clin Oncol; 2007 Mar 20; 25(9):1027-32. PubMed ID: 17312332
    [Abstract] [Full Text] [Related]

  • 11. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
    Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR.
    J Clin Oncol; 2006 Aug 01; 24(22):3583-9. PubMed ID: 16877725
    [Abstract] [Full Text] [Related]

  • 12. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct 01; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL.
    Crit Care Med; 2006 Sep 01; 34(9):2310-6. PubMed ID: 16878035
    [Abstract] [Full Text] [Related]

  • 17. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D, George MJ, Harrison LB.
    Cancer; 2003 Sep 01; 98(5):1072-9. PubMed ID: 12942577
    [Abstract] [Full Text] [Related]

  • 18. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.
    Savonije JH, van Groeningen CJ, van Bochove A, Honkoop AH, van Felius CL, Wormhoudt LW, Giaccone G.
    Eur J Cancer; 2005 Jul 01; 41(11):1560-9. PubMed ID: 15953714
    [Abstract] [Full Text] [Related]

  • 19. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
    Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.
    J Clin Oncol; 2010 May 01; 28(13):2239-45. PubMed ID: 20368566
    [Abstract] [Full Text] [Related]

  • 20. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
    Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA.
    Cancer; 2006 Oct 15; 107(8):1909-17. PubMed ID: 16977654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.